UBS AM
AXSM icon

UBS AM’s Axsome Therapeutics AXSM Stock Holding History

UBS AM’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16M Buy
94,937
+7,688
+9% +$1.33M ﹤0.01% 969
2025
Q4 		$15.9M Buy
87,249
+558
+0.6% +$77.9K ﹤0.01% 931
2025
Q3 		$10.5M Sell
86,691
-47,410
-35% -$5.34M ﹤0.01% 1049
2025
Q2 		$14M Buy
134,101
+59,209
+79% +$6.27M ﹤0.01% 1191
2025
Q1 		$8.73M Buy
74,892
+17,250
+30% +$1.97M ﹤0.01% 1288
2024
Q4 		$4.88M Buy
57,642
+9,928
+21% +$913K ﹤0.01% 1626
2024
Q3 		$4.29M Sell
47,714
-8,479
-15% -$740K ﹤0.01% 1654
2024
Q2 		$4.52M Buy
56,193
+27,352
+95% +$2.03M ﹤0.01% 1545
2024
Q1 		$2.3M Sell
28,841
-1,168
-4% -$98K ﹤0.01% 1623
2023
Q4 		$2.39M Sell
30,009
-4,391
-13% -$294K ﹤0.01% 1598
2023
Q3 		$2.4M Buy
34,400
+9,565
+39% +$715K ﹤0.01% 1530
2023
Q2 		$1.53M Hold
24,835
– – ﹤0.01% 1797
2023
Q1 		$1.53M Sell
24,835
-2,119
-8% -$139K ﹤0.01% 1797
2022
Q4 		$2.08M Buy
26,954
+1,951
+8% +$117K ﹤0.01% 1507
2022
Q3 		$1.12M Buy
25,003
+2,936
+13% +$147K ﹤0.01% 1903
2022
Q2 		$845K Sell
22,067
-892
-4% -$28.2K ﹤0.01% 2059
2022
Q1 		$950K Hold
22,959
– – ﹤0.01% 2177
2021
Q4 		$867K Hold
22,959
– – ﹤0.01% 2286
2021
Q3 		$757K Sell
22,959
-4,666
-17% -$182K ﹤0.01% 2302
2021
Q2 		$1.86M Buy
27,625
+2,778
+11% +$167K ﹤0.01% 1884
2021
Q1 		$1.41M Sell
24,847
-2,196
-8% -$154K ﹤0.01% 1917
2020
Q4 		$2.2M Sell
27,043
-630
-2% -$47.1K ﹤0.01% 1642
2020
Q3 		$1.97M Buy
27,673
+545
+2% +$42.5K ﹤0.01% 1547
2020
Q2 		$2.23M Buy
27,128
+8,635
+47% +$665K ﹤0.01% 1475
2020
Q1 		$1.09M Sell
18,493
-4,815
-21% -$392K ﹤0.01% 1666
2019
Q4 		$2.41M Buy
23,308
+10,064
+76% +$406K ﹤0.01% 1514
2019
Q3 		$268K Sell
13,244
-9,983
-43% -$257K ﹤0.01% 2488
2019
Q2 		$598K Buy
+23,227
New +$466K ﹤0.01% 2132

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM's AXSM Position: Q1 2026 in Review

UBS AM increased its Axsome Therapeutics (AXSM) stake by 8.8% in Q1 2026, buying an estimated $1.33M and bringing the position to 94,937 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #969.

UBS AM first reported a position in AXSM in Q2 2019 and has held it in 28 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • UBS AM held 94,937 shares of Axsome Therapeutics worth $16M as of Q1 2026.
  • UBS AM bought 7,688 Axsome Therapeutics shares in Q1 2026, an estimated $1.33M.
  • Axsome Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #969 holding.
  • UBS AM first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.